查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862582

藥物發現資訊學市場按組件、應用、部署類型、最終用戶和治療領域分類－2025-2032年全球預測

Drug Discovery Informatics Market by Component, Application, Deployment, End User, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物發現資訊學市場將成長至 69.5 億美元，複合年成長率為 10.20%。

關鍵市場統計數據
基準年 2024 31.9億美元
預計年份：2025年 35.1億美元
預測年份 2032 69.5億美元
複合年成長率 (%) 10.20%

藥物發現資訊學發展架構以及組織為整合運算平台和服務所應採取的策略重點

藥物發現資訊學融合了計算科學、生物學和轉化研究，徹底改變了治療假設的生成、檢驗和推進方式。生物資訊學和化學資訊學的創新拓展了In Silico方法的範圍和精確度，使研究團隊能夠以前所未有的深度探索基因組、蛋白質組和化學空間。此外，相關服務能夠將平台輸出轉換為可部署的工作流程，並透過諮詢、系統整合和持續支持，確保模型輸出與實驗室執行之間的無縫銜接。

識別技術、服務和管治的融合趨勢，這些趨勢將重塑藥物發現資訊學和整個研究生態系統的夥伴關係模式。

由於調查方法日趨成熟、平台整合以及雲端原生運算範式的普及，藥物發現資訊學領域正在經歷變革。基於多組體學資料集訓練的機器學習模型如今已常規與基於物理的模擬相結合，分子對接、QSAR建模和虛擬篩檢方法的通量和預測精度也在不斷提高。這些技術進步得益於對可重複性和可解釋性的日益重視，促使供應商和研究團隊加強對溯源管理、模型檢驗框架和透明性能基準的投入。

評估2025年關稅相關貿易變化對藥物研發專案中供應商多元化、合約創新和策略佈局選擇的影響

2025年美國關稅環境的調整帶來了一層商業性不確定性，這種不確定性波及採購、供應商策略和國際合作。在硬體、專用運算設備和某些軟體相關服務與跨境貿易密切相關的領域，關稅正促使各組織重新評估籌資策略和總成本。事實上，採購團隊正在擴大供應商範圍，納入國內供應商和區域合作夥伴，一些組織還在協商簽訂多年期契約，以應對關稅的進一步波動。

分析組件、應用、部署、最終用戶和治療領域細分，以識別差異化的部署模式和策略機會領域。

細分市場分析闡明了不同組件、應用、部署模式、最終用戶和治療領域的產能和需求分佈情況，揭示了差異化的部署模式和能力缺口。按組件分類，市場由「服務」和「軟體」兩部分組成。服務包括諮詢、系統整合和支援/維護能力，這些能力彌合了平台功能與實驗室操作之間的差距；而軟體則細分為生物資訊學和化學資訊學。在生物資訊學領域，基因組資訊學、蛋白質組學和轉錄組學分別反映了不同的數據模式和分析需求。在化學資訊學領域，分子對接、QSAR建模和虛擬篩檢代表了支援化合物優先排序和虛擬先導化合物發現的融合方法。

繪製區域管理體制、人才集中度和基礎設施現狀如何影響全球擴張選擇、夥伴關係和合作模式的圖譜

區域趨勢正在影響各組織部署資訊解決方案和建構夥伴關係的方式，每個區域都呈現不同的監管環境、人才儲備和基礎設施考量。在美洲，對轉化研究的大力投入、生物製藥總部的高度集中以及成熟的雲端運算和高效能運算 (HPC) 能力，共同促進了整合生物資訊學和化學資訊學平台的快速普及。這種環境支持學術界和商業夥伴之間的複雜合作，強調互通性和能夠支持跨機構端到端藥物發現工作流程的供應商生態系統。

分析平台供應商、整合商、服務供應商和研究合作夥伴如何建立能力和合作夥伴關係，以提供端到端的藥物發現解決方案。

藥物發現資訊學領域的公司在平台開發、服務產品和整合夥伴關係方面展現出差異化的能力。成熟的軟體供應商專注於建立強大且檢驗的生物資訊學和化學資訊學工具鏈，並投資於模組化架構，使客戶能夠整合基因組學、蛋白質組學和分子建模的輸出結果。同時，越來越多的專業公司正在利用機器學習和基於物理的模型來提高ADMET預測、虛擬篩檢和基於結構的藥物設計的預測性能。他們通常與大規模整合商合作，將解決方案部署到工業客戶。

領導者可以採取哪些切實可行的策略步驟來建立可互通的平台、平衡採用風險並加強模型管治，從而加速其藥物研發進程？

產業領導者應採取一系列實際有效且影響深遠的行動，使組織能力與新興的資訊需求保持一致，並保障策略彈性。首先，應優先考慮可互通的架構和標準化的資料模型，以便在無需大規模重新設計的情況下整合新工具。這有助於減少供應商鎖定，並加速跨職能工作流程。其次，應採用混合部署策略，將本地資源的安全性和可控性與雲端環境的彈性運算能力和協作優勢結合。這種方法允許團隊將敏感資料工作流程分配到託管環境中，同時利用公共雲端進行運算密集型模擬。

採用混合調查方法，結合相關人員訪談和二手分析，得出檢驗的研究結果和透明的限制。

本分析的調查方法結合了質性研究和來自多個資訊來源的系統性綜合分析，旨在得出有效且可操作的見解。主要研究包括對製藥和生物技術公司、合約研究組織 (CRO)、平台供應商和學術研究機構的關鍵相關人員進行訪談，重點關注採購行為、實施決策、整合挑戰和治療領域優先事項。這些訪談旨在從實踐者的觀點了解功能、痛點和策略權衡，受訪者涵蓋了計算科學家、研發總監、營運經理等多個職位。

總結了影響電腦輔助藥物發現和轉化研究未來的方法論、商業性和營運促進因素。

累積分析表明，該領域正處於轉型期。調查方法的進步、平台的成熟以及商業性動態的轉變正在共同改變藥物發現的概念和實施方式。資訊科學能力不再是輔助工具，而是支持假設生成和候選藥物推進的核心要素，而軟體平台和服務之間的相互作用決定了機構將計算洞察轉化為實際應用的程度。受地域和關稅等商業性因素驅動，對採購選擇和部署架構構成實際限制。同時，按應用和治療領域進行細分，可以明確哪些領域的投資能夠帶來最大的科學和營運回報。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過將人工智慧驅動的表現型篩檢資料整合到雲端基礎的資訊平台中，加速新型靶點的識別。
  • 引入聯邦學習框架，實現臨床前藥物發現工作流程中機構間安全資料共用
  • 實現量子機器學習演算法，用於複雜化學庫的高通量虛擬篩檢
  • 應用多體學資料整合工具建構精準醫療發展預測模型
  • 利用先進的自然語言處理技術，在藥物研發流程中擴展真實世界證據分析
  • 引入基於區塊鏈的溯源追蹤系統，以檢驗化合物並提高研究的可重複性。
  • 利用數位雙胞胎模型模擬患者特異性藥物反應並最佳化先導化合物選擇

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 藥物發現資訊學市場（依組件分類）

  • 服務
    • 諮詢
    • 一體化
    • 支援與維護
  • 軟體
    • 生物資訊學
      • 基因組資訊學
      • 蛋白質體學資訊學
      • 轉錄組學資訊學
    • 化學資訊學
      • 分子對接
      • QSAR建模
      • 虛擬篩檢

9. 按應用分類的藥物發現資訊學市場

  • ADMET預測
    • 代謝預測
    • 藥物動力學預測
    • 毒性預測
  • 線索發現
    • 高通量篩檢資訊學
    • 從點擊量到銷售線索的資訊學
    • 虛擬篩檢資訊學
  • 分子建模模擬
    • 分子動力學
    • QSAR建模
    • 基於結構的設計
  • 目標識別
    • 基因組分析
    • 蛋白質體學分析
    • 目標檢驗資訊學

第10章：按實施類型分類的藥物發現資訊學市場

  • 雲
    • 混合雲端
    • 私有雲端
    • 公共雲端
  • 本地部署
    • 客戶端/伺服器
    • 企業伺服器

第11章 以最終用戶分類的藥物發現資訊學市場

  • 學術研究機構
  • CRO（受託研究機構）
  • 製藥和生物技術公司

第12章 按治療領域分類的藥物發現資訊學市場

  • 循環系統疾病
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學

第13章 各地區藥物發現資訊學市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 藥物發現資訊學市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國藥物發現資訊學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Dassault Systemes SE
    • PerkinElmer, Inc.
    • Certara, Inc.
    • Schrodinger, Inc.
    • Genedata AG
    • Dotmatics Ltd
    • TIBCO Software Inc.
    • BioSolveIT GmbH
    • Optibrium Ltd
    • Clarivate PLC
Product Code: MRR-521BAA36EBB5

The Drug Discovery Informatics Market is projected to grow by USD 6.95 billion at a CAGR of 10.20% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.19 billion
Estimated Year [2025] USD 3.51 billion
Forecast Year [2032] USD 6.95 billion
CAGR (%) 10.20%

Framing the evolution of drug discovery informatics and the strategic priorities organizations must adopt to integrate computational platforms and services

Drug discovery informatics sits at the nexus of computational science, biology, and translational research, reshaping how therapeutic hypotheses are generated, validated, and advanced. Innovations in bioinformatics and cheminformatics have expanded the scope and precision of in silico approaches, enabling research teams to interrogate genomic, proteomic, and chemical spaces with unprecedented depth. These capabilities are complemented by services that translate platform outputs into deployable workflows, with consulting, systems integration, and ongoing support ensuring continuity between model outputs and laboratory execution.

Across organizations, this convergence is driving a shift in operational models: software platforms that once served as niche tools are now integral to discovery pipelines, while service providers are embedding advanced analytics into end-to-end solutions. As a result, cross-functional teams composed of computational scientists, bench researchers, and data engineers are becoming standard, fostering rapid iteration between hypothesis generation and empirical validation. In this context, leaders must prioritize interoperability, data provenance, and lifecycle management of computational models to preserve scientific rigor while accelerating time-to-experimentation. Understanding these dynamics is essential for stakeholders seeking to align capabilities with strategic goals and to navigate the competitive landscape of platform vendors, integrators, and research institutions.

Identifying the converging technological, service, and governance trends reshaping drug discovery informatics and partnership models across the research ecosystem

The landscape of drug discovery informatics is undergoing a transformative shift driven by methodological maturation, platform integration, and the mainstreaming of cloud-native compute paradigms. Machine learning models trained on multi-omic datasets are now routinely coupled with physics-based simulations, while molecular docking, QSAR modeling, and virtual screening methods have improved in throughput and predictive value. These technical gains are reinforced by a growing emphasis on reproducibility and explainability, prompting vendors and research groups to invest in provenance, model validation frameworks, and transparent performance benchmarks.

Concurrently, services ecosystems have evolved to provide not only implementation support but also strategic advisory roles. Consulting teams increasingly help organizations assess the fit of bioinformatics and cheminformatics solutions against internal capabilities, and integration experts orchestrate data flows between laboratory information management systems, high-performance computing resources, and cloud environments. The rise of hybrid deployment options allows organizations to balance data sensitivity with scalability, enabling secure on-premise processing for protected datasets and public cloud bursts for compute-intensive simulations. Taken together, these developments are reshaping partnership models between technology providers, contract research organizations, and end users, creating new pathways for innovation while raising the bar for governance and interoperability.

Assessing how tariff-related trade shifts in 2025 are prompting supplier diversification, contractual innovation, and strategic deployment choices in discovery programs

The United States tariff environment in 2025 introduced layers of commercial uncertainty that ripple across procurement, supplier strategies, and international collaborations. Where hardware, specialized computational appliances, and certain software-linked services intersect with cross-border trade, tariffs have prompted organizations to reassess sourcing strategies and total cost of engagement. In practice, procurement teams have expanded supplier panels to include domestic vendors and regional partners, and some organizations have negotiated multi-year agreements to protect against further tariff volatility.

These adjustments have implications for research timelines and capital planning. R&D leaders are increasingly evaluating the tradeoffs between acquiring on-premise infrastructure and adopting cloud-based alternatives that mitigate hardware import exposure. Similarly, partnerships with contract research organizations and platform providers are being structured to share risk, with clauses that address tariff-related cost changes and delivery contingencies. In addition, tariff-driven supply chain realignments have intensified interest in regionalized data processing and storage, both to reduce exposure and to meet evolving regulatory obligations. Ultimately, the cumulative impact of tariffs is less a single cost shock and more a stimulus for strategic supplier diversification, contractual innovation, and accelerated adoption of deployment models that decouple computational capacity from geopolitically sensitive hardware supply chains.

Unpacking component, application, deployment, end-user, and therapeutic area segmentation to reveal differentiated adoption patterns and strategic opportunity spaces

Segmentation analysis clarifies how capabilities and demand are distributed across components, applications, deployments, end users, and therapeutic areas, revealing differentiated adoption patterns and capability gaps. By component, the market comprises Services and Software; Services encompasses consulting, systems integration, and support and maintenance functions that bridge the gap between platform capabilities and laboratory operations, while Software divides into Bioinformatics and Cheminformatics. Within Bioinformatics, genomics informatics, proteomics informatics, and transcriptomics informatics reflect distinct data modalities and analytic requirements; within Cheminformatics, molecular docking, QSAR modeling, and virtual screening represent convergent methods that support compound prioritization and virtual hit discovery.

Application segmentation highlights how analytical techniques are applied: ADMET prediction spans metabolism, pharmacokinetics, and toxicity prediction workflows that inform early attrition mitigation; lead discovery combines high-throughput screening informatics, hit-to-lead processing, and virtual screening informatics to accelerate candidate selection; molecular modeling simulation includes molecular dynamics, QSAR modeling, and structure-based design used to refine candidates; and target identification blends genomic and proteomic analyses with target validation informatics to prioritize biological hypotheses. Deployment choices manifest as cloud and on-premise models; cloud offerings differentiate across hybrid cloud, private cloud, and public cloud options, while on-premise deployments range from client-server to enterprise server implementations. End users include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, each exhibiting unique procurement behaviors, risk tolerances, and demands for customization. Therapeutic area segmentation spans cardiovascular disease, infectious disease, metabolic disorders, neuroscience, and oncology, reflecting both scientific complexity and investment focus. Understanding these segments in an integrated manner enables targeted capability development and market-facing strategies that align technological strengths with user needs and therapeutic priorities.

Mapping how regional regulatory regimes, talent concentrations, and infrastructure realities influence deployment choices, partnerships, and collaboration models globally

Regional dynamics are shaping how organizations deploy informatics solutions and structure partnerships, with each geography presenting distinct regulatory landscapes, talent pools, and infrastructure considerations. In the Americas, strong investment in translational research, a deep concentration of biopharma headquarters, and established cloud and HPC capacity combine to favor rapid adoption of integrated bioinformatics and cheminformatics platforms. This environment supports complex collaborations between academic centers and commercial partners, and it places a premium on interoperability and vendor ecosystems that can support end-to-end discovery workflows across diverse institutions.

Europe, the Middle East, and Africa present a heterogeneous mix of regulatory regimes and research ecosystems. In parts of Europe, stringent data protection and regional research funding frameworks encourage hybrid deployment models and strong emphasis on data governance. Meanwhile, pockets of innovation across the region drive demand for localized expertise and integration services that can adapt global platforms to regional research priorities. In the Asia-Pacific region, rapid expansion of biotech activity, sizable talent pools in computational biology and chemistry, and policy initiatives that prioritize innovation have catalyzed adoption of cloud-native solutions and public-private partnerships. However, organizations in this region also emphasize cost-efficiency and scalable deployment models that can accommodate fast-growing research portfolios. Across all regions, cross-border collaborations and virtualized research networks are increasing, creating new imperatives for standardized data exchange, compliance, and secure collaboration practices.

Profiling how platform vendors, integrators, service providers, and research partners are organizing capabilities and alliances to deliver end-to-end discovery solutions

Companies operating in the drug discovery informatics space exhibit differentiated capabilities across platform development, service delivery, and integrative partnerships. Established software vendors focus on building robust, validated toolchains for bioinformatics and cheminformatics, investing in modular architectures that enable customers to combine genomic, proteomic, and molecular modeling outputs. Simultaneously, a growing cohort of specialized firms leverages machine learning and physics-informed models to enhance predictive performance in ADMET prediction, virtual screening, and structure-based design, often partnering with larger integrators to reach enterprise customers.

Service-oriented organizations, including consulting firms and systems integrators, play a pivotal role in helping end users translate platform capabilities into operational workflows. These providers are extending offerings beyond tactical implementation to include model governance, data harmonization, and continuous performance monitoring. Contract research organizations are increasingly embedding informatics capabilities into trial and preclinical workflows, while academic spinouts contribute novel algorithms and domain expertise that accelerate scientific breakthroughs. Strategic alliances between platform vendors, cloud providers, and CROs are becoming more common, enabling bundled offerings that reduce integration friction for customers. Observed across the ecosystem is an emphasis on open interfaces, standardized data models, and partnership structures that distribute risk while preserving the capacity for rapid innovation.

Practical strategic moves for leaders to build interoperable platforms, balance deployment risks, and strengthen model governance to accelerate discovery pipelines

Industry leaders should pursue a set of pragmatic, high-impact actions to align organizational capabilities with emerging informatics demands and to protect strategic flexibility. First, prioritize interoperable architectures and standardized data models so that new tools can be integrated without extensive reengineering; this reduces vendor lock-in and accelerates cross-functional workflows. Second, adopt a hybrid deployment strategy that balances the security and control of on-premise resources with the elastic compute and collaboration benefits of cloud environments. This approach allows teams to allocate sensitive data workflows to controlled environments while leveraging public cloud for compute-intensive simulations.

Third, strengthen supplier diversification and contractual mechanisms to manage geopolitical and tariff-related risks. Include clauses that address cost adjustments and delivery contingencies, and cultivate regional supplier relationships where appropriate. Fourth, invest in workforce development by combining computational training for wet-lab scientists with domain education for data engineers, building multidisciplinary teams capable of iterating rapidly between models and experiments. Fifth, establish robust model governance frameworks that encompass validation protocols, provenance tracking, and performance monitoring, ensuring reproducibility and regulatory readiness. Finally, pursue targeted partnerships with academic centers and CROs to access specialized assays and validation pathways, thereby shortening the route from in silico prediction to empirically supported candidate progression.

Explaining the mixed-method research approach that integrates stakeholder interviews and secondary analysis to produce validated insights and transparent limitations

The research methodology underpinning this analysis combined multi-source qualitative inquiry with structured synthesis to produce defensible, actionable insights. Primary research included interviews with key stakeholders across pharmaceutical and biotechnology companies, contract research organizations, platform vendors, and academic research groups, focusing on procurement behavior, deployment decisions, integration challenges, and therapeutic area priorities. These engagements were designed to capture practitioner perspectives on capabilities, pain points, and strategic tradeoffs, and interview participants represented computational scientists, R&D leaders, and operations managers.

Secondary research reviewed technical literature, vendor documentation, and publicly available case studies to contextualize practitioner testimony and to validate technical trends. Data synthesis emphasized triangulation: where multiple independent sources converged on similar findings, confidence in the insight increased. Segmentation was applied along component, application, deployment, end-user, and therapeutic area dimensions to reflect how capabilities and demand differ across use cases. Limitations of the methodology include potential selection bias in stakeholder participation and the rapid pace of technological change that can outdate specific tool-level details; to mitigate these risks, the approach prioritized thematic patterns and structural dynamics that are robust across vendors and geographies. Ethical considerations guided the research, including anonymization of interview responses and adherence to consent protocols for proprietary information.

Concluding insights that synthesize methodological, commercial, and operational drivers shaping the future of computational discovery and translational research

The cumulative analysis highlights a field in motion: methodological advances, platform maturation, and shifting commercial dynamics are converging to reshape how drug discovery is conceptualized and executed. Informatics capabilities are no longer auxiliary tools but central enablers of hypothesis generation and candidate progression, and the interplay between software platforms and services determines the degree to which organizations can operationalize computational insights. Regional and tariff-driven commercial factors introduce practical constraints that influence procurement choices and deployment architectures, while segmentation by application and therapeutic area clarifies where investments will yield the greatest scientific and operational returns.

For research leaders and commercial strategists, the imperative is clear: prioritize modular, governed informatics ecosystems that support reproducibility, integrate with laboratory operations, and scale across deployment scenarios. By aligning talent, governance, and partnership strategies with technological advances, organizations can convert computational promise into experimentally validated therapeutics. Ultimately, success hinges on the ability to maintain scientific rigor while adopting adaptive procurement and deployment practices that absorb commercial volatility and accelerate translational progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven phenotypic screening data into cloud-based informatics platforms to accelerate novel target identification
  • 5.2. Adoption of federated learning frameworks for secure cross-institutional data sharing in preclinical drug discovery workflows
  • 5.3. Implementation of quantum machine learning algorithms for high-throughput virtual screening of complex chemical libraries
  • 5.4. Application of multi-omics data integration tools to inform predictive models for precision therapeutic development
  • 5.5. Expansion of real-world evidence analytics in drug discovery pipelines using advanced natural language processing approaches
  • 5.6. Deployment of blockchain-enabled provenance tracking systems for chemical compound validation and research reproducibility
  • 5.7. Utilization of digital twin modeling to simulate patient-specific drug responses and optimize lead compound selection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Informatics Market, by Component

  • 8.1. Services
    • 8.1.1. Consulting
    • 8.1.2. Integration
    • 8.1.3. Support And Maintenance
  • 8.2. Software
    • 8.2.1. Bioinformatics
      • 8.2.1.1. Genomics Informatics
      • 8.2.1.2. Proteomics Informatics
      • 8.2.1.3. Transcriptomics Informatics
    • 8.2.2. Cheminformatics
      • 8.2.2.1. Molecular Docking
      • 8.2.2.2. Qsar Modeling
      • 8.2.2.3. Virtual Screening

9. Drug Discovery Informatics Market, by Application

  • 9.1. Admet Prediction
    • 9.1.1. Metabolism Prediction
    • 9.1.2. Pharmacokinetics Prediction
    • 9.1.3. Toxicity Prediction
  • 9.2. Lead Discovery
    • 9.2.1. High Throughput Screening Informatics
    • 9.2.2. Hit To Lead Informatics
    • 9.2.3. Virtual Screening Informatics
  • 9.3. Molecular Modeling Simulation
    • 9.3.1. Molecular Dynamics
    • 9.3.2. Qsar Modeling
    • 9.3.3. Structure Based Design
  • 9.4. Target Identification
    • 9.4.1. Genomic Analysis
    • 9.4.2. Proteomic Analysis
    • 9.4.3. Target Validation Informatics

10. Drug Discovery Informatics Market, by Deployment

  • 10.1. Cloud
    • 10.1.1. Hybrid Cloud
    • 10.1.2. Private Cloud
    • 10.1.3. Public Cloud
  • 10.2. On Premise
    • 10.2.1. Client Server
    • 10.2.2. Enterprise Server

11. Drug Discovery Informatics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Biotechnology Companies

12. Drug Discovery Informatics Market, by Therapeutic Area

  • 12.1. Cardiovascular Diseases
  • 12.2. Infectious Diseases
  • 12.3. Metabolic Disorders
  • 12.4. Neuroscience
  • 12.5. Oncology

13. Drug Discovery Informatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Informatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Informatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Dassault Systemes SE
    • 16.3.2. PerkinElmer, Inc.
    • 16.3.3. Certara, Inc.
    • 16.3.4. Schrodinger, Inc.
    • 16.3.5. Genedata AG
    • 16.3.6. Dotmatics Ltd
    • 16.3.7. TIBCO Software Inc.
    • 16.3.8. BioSolveIT GmbH
    • 16.3.9. Optibrium Ltd
    • 16.3.10. Clarivate PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRUG DISCOVERY INFORMATICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRUG DISCOVERY INFORMATICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2024 (USD MILLIO